Calls are open

European Innovation Council (EIC) Pathfinder

Calls are open, Euripo I programmes, Programme has started / By

The European Innovation Council (EIC) supports innovations with breakthrough and market-creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition and EIC Accelerator. EIC Pathfinder supports projects focusing on early-stage scientific innovation with the potential of developing scientific breakthroughs.
In 2024, two types of calls for proposals were published:
• EIC Pathfinder Open (closed)
• EIC Pathfinder Challenges (closed)
Analogous calls for proposals are planned for 2025.

European Research Council (ERC) Proof of Concept

Calls are open, Euripo I programmes, Programme has started / By

The European Research Council (ERC) supports frontier research in any field. It is open to investigators worldwide, as long as the host institution (HI) of the Principal Investigator (PI) that receives ERC funding is established in a Member State or a country associated to Horizon Europe.
The ERC Proof of Concept programme supports the further development of projects funded by other ERC support programmes in an earlier stage.
A call for proposals was published in November 2024, with multiple cut-off dates in 2025.

European Research Council (ERC) Consolidator Grant

Calls are open, Euripo I programmes, Programme has started / By

The European Research Council (ERC) supports frontier research in any field. It is open to Principal Investigators (PIs) worldwide, as long as the Host Institution (HI) of the principal investigator that receives ERC funding is established in a Member State or a country associated to Horizon Europe. The ERC has four major grant programmes: Starting Grants, Consolidator Grants, Advanced Grants, and Synergy Grants.
The ERC Consolidator Grant supports researchers with 7-12 years of experience.
A call for proposals opened in September 2024 and will close in January 2025.

European Partnership on Transforming Health and Care Systems (THCS)

Calls are open, Euripo I programmes, Programme is in development / By

The European Partnership on Transforming Health and Care Systems (THCS) aims to support the transition towards more sustainable, resilient, innovative and high-quality people-centred health and care systems by pooling resources to tackle future health challenges.
In 2024, two calls for proposals were published:
• Joint Transnational Call (JTC) 2024 – Innovate to Prevent, focusing on the implementation of innovative person-centred health and care models addressing prevention strategies (closed)
• JTC 2025 – Better case closer to home: Enhancing primary and community care, focusing on strengthening primary and community health and care systems and providing policy and decision-makers with the necessary knowledge and tools to govern the transitions needed in the primary and community care sector (open)

European Innovation Council (EIC) Accelerator

Calls are open, Euripo I programmes, Programme has started / By

The European Innovation Council (EIC) supports innovations with breakthrough and market-creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition and EIC Accelerator. EIC Accelerator supports smaller actors in developing innovative solutions that would allow them to scale up.
Under the 2024 work programme, two types of calls for proposals opened : EIC Accelerator Open for projects in any field of science, technology or application without predefined thematic priorities, and EIC Accelerator Challenges for projects that match any of the predefined thematic areas of the Accelerator Challenges. All the calls are now closed.
Under the 2025 work programme, the same calls are now open for the short application until December 2025.

European Investment Bank (EIB)

Calls are open, Euripo I programmes, Programme has started / By

The European Investment Bank (EIB) works closely with other EU institutions to foster European integration, promote the development of the EU and support EU policies in over 160 countries around the world. It offers loans, guarantees, equity investments and advisory services to help finance large and small-scale investment projects that support EU policy objectives.

European Innovation Council (EIC) Transition

Calls are open, Euripo I programmes, Programme has started / By

The European Innovation Council (EIC) supports innovations with breakthroughs and market-creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition, and EIC Accelerator. EIC Transition supports the maturation and validation of novel technology in the lab and in relevant application environments, as well as the development of a business case and business model to commercialise this novel technology.
In 2024, one call for proposals was published (closed). An analogous call is planned for 2025.

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide: https://ec.europa.eu/docsroom/documents/42921
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:
    Monitoring

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:
    Monitoring

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain